Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
Interventions: pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nipah Virus Infection
Interventions: PHV02, Placebo; Biological · Other
Lead sponsor: Public Health Vaccines LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Adults
Interventions: Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more

Conditions: Rabies
Interventions: Purified Vero Rabies Vaccine (VRVg), Imovax® Rabies: inactivated rabies vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 342 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Pembroke Pines, Florida • South Miami, Florida • Boise, Idaho + 2 more

Conditions: Influenza
Interventions: 2016-2017 Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 20 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Human Papilloma Virus
Interventions: Gardasil9; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 4 Years to 8 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronavirus (SARS-CoV)
Interventions: Aluminum hydroxide, Placebo, SARS-CoV; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chula Vista, California • Gardena, California • Long Beach, California + 24 more

Conditions: Healthy
Interventions: RSV Vaccine, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT 60 µg, RSV MAT 120 µg, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more

Conditions: SARS-CoV Infection, Covid19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination); Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 12 Years and older
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more

Conditions: Influenza
Interventions: Influenza Vaccination; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 6 Months to 59 Months
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Influenza Vaccine 2004-2005 Paediatric Formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK 134612, Menactra®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Chandler, Arizona • Paramount, California • Sacramento, California + 19 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Newton, Kansas • Syracuse, New York • Ellensburg, Washington

Conditions: Varicella, Rubella, Mumps, Measles
Interventions: Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 14 Months
Enrollment: 1,851 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 141
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more

Conditions: Shigellosis
Interventions: Flexyn2a, Placebo, Flexyn2a plus adjuvant; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Influenza
Interventions: Fluzone®: Influenza virus vaccine 2004-2005 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 10 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 3
States / cities: Torrance, California • Baltimore, Maryland • St Louis, Missouri

Conditions: Pulmonary TB
Interventions: ID93 + GLA-SE; Biological
Lead sponsor: Access to Advanced Health Institute (AAHI); Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza, Swine-origin A/H1N1 Influenza
Interventions: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA), Normal saline solution (placebo); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 0 Years to 40 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST, Ovarian Cancer
Interventions: HER-2 vaccine, Extension HER-2 vaccine trial at OBD; Biological
Lead sponsor: Robert Wesolowski; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma
Interventions: Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 24
States / cities: Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more

Search by objective public record fields.

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

A Study to Learn About mRNA Vaccines Against Influenza in Adults

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

SARS Coronavirus Vaccine (SARS-CoV)

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma